[go: up one dir, main page]

WO2005032589A8 - Ｇｖｈｄの予防及び治療 - Google Patents

Ｇｖｈｄの予防及び治療

Info

Publication number
WO2005032589A8
WO2005032589A8 PCT/JP2004/014277 JP2004014277W WO2005032589A8 WO 2005032589 A8 WO2005032589 A8 WO 2005032589A8 JP 2004014277 W JP2004014277 W JP 2004014277W WO 2005032589 A8 WO2005032589 A8 WO 2005032589A8
Authority
WO
WIPO (PCT)
Prior art keywords
gvhd
cells
organ injury
inhibiting
specifically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2004/014277
Other languages
English (en)
French (fr)
Other versions
WO2005032589A1 (ja
Inventor
Kouji Matsushima
Satoshi Ueha
Toshio Imai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Japan Science and Technology Agency
Original Assignee
Eisai Co Ltd
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd, Japan Science and Technology Agency filed Critical Eisai Co Ltd
Priority to EP04788343A priority Critical patent/EP1671648A4/en
Priority to JP2005514440A priority patent/JPWO2005032589A1/ja
Publication of WO2005032589A1 publication Critical patent/WO2005032589A1/ja
Publication of WO2005032589A8 publication Critical patent/WO2005032589A8/ja
Priority to US11/393,283 priority patent/US20060233710A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PCT/JP2004/014277 2003-10-02 2004-09-29 Ｇｖｈｄの予防及び治療 Ceased WO2005032589A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04788343A EP1671648A4 (en) 2003-10-02 2004-09-29 PREVENTION AND TREATMENT OF GVHD
JP2005514440A JPWO2005032589A1 (ja) 2003-10-02 2004-09-29 Ｇｖｈｄの予防及び治療
US11/393,283 US20060233710A1 (en) 2003-10-02 2006-03-30 Prevention and treatment for GVHD

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-345058 2003-10-02
JP2003345058 2003-10-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/393,283 Continuation-In-Part US20060233710A1 (en) 2003-10-02 2006-03-30 Prevention and treatment for GVHD

Publications (2)

Publication Number Publication Date
WO2005032589A1 WO2005032589A1 (ja) 2005-04-14
WO2005032589A8 true WO2005032589A8 (ja) 2005-06-16

Family

ID=34419436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/014277 Ceased WO2005032589A1 (ja) 2003-10-02 2004-09-29 Ｇｖｈｄの予防及び治療

Country Status (4)

Country Link
US (1) US20060233710A1 (ja)
EP (1) EP1671648A4 (ja)
JP (1) JPWO2005032589A1 (ja)
WO (1) WO2005032589A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046739A1 (ja) 2004-10-29 2006-05-04 Eisai R & D Management Co., Ltd. 炎症性疾患治療剤
JP2007051980A (ja) * 2005-08-19 2007-03-01 Okayama Univ 移植片対宿主病の検査方法、検査用試薬ならびに予防薬および／または治療薬のスクリーニング方法
WO2009001545A1 (ja) 2007-06-22 2008-12-31 Sapporo Medical University 移植片対宿主疾患の検査および治療方法
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
US20180185421A1 (en) * 2016-08-29 2018-07-05 Tokyo Metropolitan Government Composition comprising fecal microbiota
CN114732807A (zh) * 2022-03-27 2022-07-12 苏州大学 米托蒽醌在制备预防或治疗急性移植物抗宿主病药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011950A1 (en) * 1998-08-31 2000-03-09 Oregon Health Science University Prevention of cell migration initiation with cmv us28 receptor antagonists
JP4263391B2 (ja) * 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine

Also Published As

Publication number Publication date
US20060233710A1 (en) 2006-10-19
WO2005032589A1 (ja) 2005-04-14
EP1671648A4 (en) 2009-07-08
EP1671648A1 (en) 2006-06-21
JPWO2005032589A1 (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2008030891A3 (en) Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
WO2006052718A3 (en) Farnesyltransferase inhibitors for treating sepsis
EP1599213A4 (en) CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
WO2005060520A3 (en) ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
EP2371859A3 (en) Treatment of TNF alpha related disorders
WO2005049084A3 (en) Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
WO2005102387A3 (en) Therapeutic use of anti-cs1 antibodies
WO2008157787A3 (en) Hydroxylated tolans and related compounds in the treatment of cancer
WO2008019376A3 (en) Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2006106311A3 (en) Combination treatment methods for treating sex-hormone dependent disease and fertility treatment
WO2005032589A8 (ja) Ｇｖｈｄの予防及び治療
WO2006014913A3 (en) Inhibitors of 5'-methylthioadenosine phosphorylase and 5'methylthioadenosine/s-adenosylhomocysteine nucleosidase
WO2004041215A3 (en) Methods for treating gastroesophageal reflux disease
WO2006009975A3 (en) Histamine to treat disorders affecting muscle function
WO2007120720A3 (en) Uses and compositions for treatment of crohn's disease
WO2007035489A3 (en) Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2006041800A3 (en) 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated kv1.3 potassium channel
PT1556489E (pt) Composi??o farmac?utica para a prepara??o de um medicamento destinado a tratar e/ou a prevenir uma patologia ligada a uma conduta obsessiva ou a obesidade
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
WO2005124563A9 (en) Compounds and kits for treating muscle disorders and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005514440

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004788343

Country of ref document: EP

Ref document number: 11393283

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004788343

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11393283

Country of ref document: US